Visionary Ventures
Venture capitalNewport Beach · Series A–Late Stage · 13 people tracked
Investment thesis
Visionary Ventures believes that better information produces better investments and superior returns. It builds an advantage by partnering with Key Opinion Leaders (KOLs), industry experts, and strategic acquirers who source, vet, and advocate deals through a peer-review process. Beyond returns, the firm prioritizes backing companies that serve unmet or underserved markets and create broader societal impact. It seeks visionary, proven entrepreneurs turning ideas into market-leading businesses, focusing on the Series A to commercialization phase with target investments of $5M to $15M.
Source: firm website, verified Aug 3, 2026.
Team · 13 people
from the firm's website
What they invest in
from 6 of 15 portfolio companiesBiotech ×5Healthtech ×2Medical Devices ×2
HQs:United States×6
Investments · 15 tracked
founders shown can be your intro pathONL Therapeutics is a clinical-stage biopharmaceutical company developing neuroprotective treatments for retinal diseases including retinal detachment, geographic atrophy, and glaucoma.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Executive Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)Loic Couraud(Director)William Brinkerhoff(Director)Mark Hooper(Director)
BiotechSeattle, US
GREG KUNST(Executive Officer, Director)PATRICK LALLY(Director)JEANNETTE BANKES(Director)LINK WILLIAM(Director)DAVID ROSTOV(Executive Officer)ANDREW ELBARDISSI(Director)
HealthtechReno, US
Charles Warden(Director)Brian Walsh(Executive Officer, Director)Bruce J. Brumfield, Jr.(Director)Glenn Rockman(Director)Jim Mazzo(Director)Tsontcho Ianchulev(Executive Officer, Director)
Iantrek develops medical devices and technologies for micro-interventional ophthalmic surgery, specifically targeting glaucoma treatment through uveoscleral pathway outflow enhancement for surgeons and ophthalmologists.
BiotechMedical DevicesElkins Park, US
Tsontcho Ianchulev(Executive Officer, Director)Michael Haydin(Executive Officer)Andrew Corley(Director)Stephen Bloch(Director)
BoardJeffry K Weinhuff(Director)Farrell Tyson(Director)
BiotechCopley, US
William Link(Director)Kevin Hershfield(Executive Officer, Director)Richard Heinick(Director)Steve Pazol(Director)Jeffry Weinhuff(Director)Tyler Stowater(Director)
Frequently asked questions
- What stage does Visionary Ventures invest at?
- Visionary Ventures invests at the Series A, Series B, Growth, Late Stage stages.
- What is Visionary Ventures's typical check size?
- Visionary Ventures typically writes checks of $5M – $15M.
- What sectors does Visionary Ventures focus on?
- Visionary Ventures focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices, Sector Agnostic.
- Where is Visionary Ventures located?
- Visionary Ventures is headquartered in Newport Beach, US.
Similar investors
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Claret Capital Partners is a European venture debt provider that finances technology, life sciences and impact companies, having deployed over €1.5bn across more than 200 companies.